In vitro activity of moxifloxacin against 923 anaerobes isolated from human intra-abdominal infections.
about
Canadian practice guidelines for surgical intra-abdominal infectionsA focus on intra-abdominal infections.Complicated intra-abdominal infections: a focus on appendicitis and diverticulitis.2013 WSES guidelines for management of intra-abdominal infections.WSES consensus conference: Guidelines for first-line management of intra-abdominal infections.National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004Moxifloxacin in the treatment of skin and skin structure infections.Global fluoroquinolone resistance epidemiology and implictions for clinical use.Toward an understanding of changes in diversity associated with fecal microbiome transplantation based on 16S rRNA gene deep sequencingAntimicrobial resistance and the management of anaerobic infections.Antimicrobial treatment for intra-abdominal infections.Antianaerobic antimicrobials: spectrum and susceptibility testing.Moxifloxacin monotherapy for treatment of complicated intra-abdominal infections: a meta-analysis of randomised controlled trials.Antimicrobials therapy of anaerobic infections.CT findings and features of postoperative abdominal infection patients with pancreatic carcinoma.Comparative in vitro susceptibilities of 396 unusual anaerobic strains to tigecycline and eight other antimicrobial agents.In vitro activities of dalbavancin and 12 other agents against 329 aerobic and anaerobic gram-positive isolates recovered from diabetic foot infections.Antimicrobial susceptibilities and clinical sources of Dialister species.In vitro activity of tigecycline and comparators against a European compilation of anaerobes collected as part of the Tigecycline Evaluation and Surveillance Trial (TEST).Clinical efficacy and correlation of clinical outcomes with in vitro susceptibility for anaerobic bacteria in patients with complicated intra-abdominal infections treated with moxifloxacin.
P2860
Q24599288-8403E1D6-3E72-4373-8A66-86E02B2436FCQ33763449-A2D0CBD6-E158-4135-9B25-65F87F4F5EC3Q34095187-6CE712B1-F7A1-46E0-BED2-36A277D4C597Q34321150-85DC1BA2-EABD-4C43-957D-CFA5075BF409Q34541183-9BCF1AE1-41B2-47F7-BCF9-14265CA78D83Q35759014-1527917A-0D2C-41FA-9FE9-B9FA2DE25860Q35919259-A189FA4D-13AF-4FEE-A534-A52CC07C457DQ36337074-9D5E48E6-7C6E-4602-B6BB-1D3CD987F1F8Q36351477-B6C06022-A413-4DB9-8E2B-403B63BCF8D2Q36901960-E4F515AC-E76B-420D-A744-C5AAFB891C63Q37000729-CA902820-E624-4A30-9BA4-63EE267B0719Q37035824-5359B644-7405-41D8-A5C5-B3C3238FD1B0Q37976854-BBB92EB4-CBE8-4D6A-A656-FC095167839BQ38586018-EC7CF35E-FCC3-422F-92AC-A6DD9280BAEDQ38622871-A3957700-5818-4CBC-BA3B-47CA3C01CF3FQ38665257-AC7116EC-4EC2-43BC-8F7C-D5731B4C5B7FQ42550139-7A91D877-D3D7-45B5-B34D-F15779EFC07FQ42909059-27744180-3ABD-40FB-A5F6-C4848A606D72Q43250358-5F4CE347-67BE-496D-BE52-13A933BA2B48Q45074770-9A4FA37C-6901-49D5-98C6-65D37702BAD0
P2860
In vitro activity of moxifloxacin against 923 anaerobes isolated from human intra-abdominal infections.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
In vitro activity of moxifloxa ...... an intra-abdominal infections.
@ast
In vitro activity of moxifloxa ...... an intra-abdominal infections.
@en
In vitro activity of moxifloxa ...... an intra-abdominal infections.
@nl
type
label
In vitro activity of moxifloxa ...... an intra-abdominal infections.
@ast
In vitro activity of moxifloxa ...... an intra-abdominal infections.
@en
In vitro activity of moxifloxa ...... an intra-abdominal infections.
@nl
prefLabel
In vitro activity of moxifloxa ...... an intra-abdominal infections.
@ast
In vitro activity of moxifloxa ...... an intra-abdominal infections.
@en
In vitro activity of moxifloxa ...... an intra-abdominal infections.
@nl
P2093
P2860
P1476
In vitro activity of moxifloxa ...... an intra-abdominal infections.
@en
P2093
C Vreni Merriam
Diane M Citron
Ellie J C Goldstein
Helen Fernandez
Kerin L Tyrrell
Yumi A Warren
P2860
P304
P356
10.1128/AAC.50.1.148-155.2006
P407
P577
2006-01-01T00:00:00Z